Biocollection in MyeloDysplastic Syndrome (P-MDS)
Launched by UNIVERSITY HOSPITAL, BREST · Apr 30, 2021
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Biocollection in MyeloDysplastic Syndrome (P-MDS), is studying a group of blood disorders known as myelodysplastic syndromes (MDS). MDS affects how the body produces blood cells, leading to issues like low blood counts and an increased risk of developing acute leukemia. Researchers want to collect biological samples from patients with MDS to help identify markers that could predict how the disease progresses. This information could ultimately help doctors make better treatment decisions based on the specific characteristics of each patient's condition.
To participate in the trial, you need to be an adult diagnosed with or suspected of having MDS and being treated at the Cancer-Hematology Institute in Brest. You’ll also need to have biological samples collected for the study and provide your consent to participate. Unfortunately, minors, pregnant women, and those who cannot provide consent due to legal reasons are not eligible. If you join the trial, you can expect to contribute to important research that may improve understanding and treatment of MDS in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Major
- • patient with or suspected of myelodysplastic syndrome (WHO definition) at diagnosis and/or during follow-up, which is managed at the level of the Cancer-Hematology Institute of the Brest CHRU
- • Presence of biological material collected within the CRB
- • Patient's consent obtained
- Exclusion Criteria :
- • Minor and pregnant woman
- • Lack of biological material collected within the CRB
- • Refusal to participate: lack of consent - Unable to consent
- • Patient under judicial protection: guardianship, curatorship ...
About University Hospital, Brest
The University Hospital of Brest is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. With a strong emphasis on interdisciplinary collaboration, the hospital serves as a hub for cutting-edge clinical trials aimed at improving treatment outcomes across various medical specialties. Leveraging its robust academic affiliations and state-of-the-art facilities, the University Hospital of Brest is committed to fostering scientific discovery and enhancing the quality of life for patients through evidence-based practices and pioneering research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brest, , France
Patients applied
Trial Officials
Nathalie Douet-Guilbert, MD,PhD
Principal Investigator
CHRU Brest
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials